Global Pharmacogenomics Market

Global Pharmacogenomics Market:

Focus on Services, Applications, Technologies, End Users, Country Data (16 Countries), and Competitive Landscape – Analysis and Forecast, 2019-2028

The global pharmacogenomics market has been witnessing a steady growth since the end of the Human Genome Project in 2003. The market is expected to continue to grow with a double digit CAGR of 6.98% during the forecast period, 2019-2028.

SKU: BH007B
Published Year: 2019
 

Pharmacogenomic services have significantly transformed the entire medical industry. With evolution of these services into direct-to-consumer tests, the global scope has been expanded to cover the entire healthcare gamut, further personalizing treatment modules. The rapid growth of clinically relevant pharmacogenomic knowledge and drugs used for patient treatment in virtually every medical specialty, is consistently aiding in the evolution of prevention-based treatment. With a critical role in the global precision medicine phenomenon, pharmacogenomics is responsible for ensuring safe and effective application of targeted therapeutics. These individualized care regimes are improving the quality of life of the patients and reducing economic, societal, and clinical burden, projecting a future of prosperity. 

Presently, service categories within the pharmacogenomics market include genotyping, SNP identification, and pharmacogenetic testing, among others. Although services are widespread, there is still considerable apprehension toward the adoption of genetic testing services in order to stratify patients for drug selection and dosage. Minimal reimbursement in developed countries such as the U.S., though restraining growth in the market, is being overcome by an increasing patient awareness that is leading to growth in the market.

The purpose of the study is to gain a holistic view of the global pharmacogenomics market in terms of various factors influencing it, including regulatory reforms, and technological advancements. The market has been segmented into ‘services’, ‘applications’, ‘technologies’, ‘end users’, and ‘regions’. The scope of this report is centered upon conducting a detailed study of the products and services allied with the pharmacogenomics market. In addition, the study also includes the exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each service, application, technology, end user, region, and company, as well as other vital information with respect to global pharmacogenomics market. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.

This research report aims at answering various aspects of the global pharmacogenomics market with the help of the key factors driving the market, the restraints, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.

The research study highlights the factors governing the industry attractiveness with Porter’s Five Forces for a comprehensive understanding of the global pharmacogenomics market. Moreover, the study includes detailed product mapping, market estimation, and analysis of key trends in multiple geographical regions, growth of pharmacogenomics market in each region for different applications, and the key strategies and developments by the prominent pharmacogenomics manufacturers and service providers.

The answers to the following key questions can be derived from this report:

•    What are the major market drivers, challenges, and opportunities in the global pharmacogenomics market?
•    What are the underlying structures resulting in the emerging trends within the global pharmacogenomics market?
•    How will each segment of the global pharmacogenomics market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2028?
•    What are the key developmental strategies which are implemented by the major players in order to sustain in the competitive market? What are the key regulatory implications in developed and developing regions for pharmacogenomics?
•    Who are the leading players with significant offerings to the global pharmacogenomics market? What is the current market dominance for each of these leading players?
•    What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2019-2028? Which pharmacogenomics service type is estimated to witness the most promising growth? 
•    What are the key applications in global pharmacogenomics market? What are the major segments of these applications? 
•    What are the major technologies that are employed in the global pharmacogenomics market? Which is the dominating technology?
•    Who are the primary end users of the global pharmacogenomics market? Which is the fastest growing end use segment in the global pharmacogenomics market? What are the services that are being provided by these end users?
•    Who are the key manufacturers and service providers in the global pharmacogenomics market, and what are their contributions? Also, what is the growth potential of each major pharmacogenomics manufacturer and service provider?
•    What is the scope of the global pharmacogenomics market in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World? Which pharmacogenomics application and service type dominate these regions?

Key trends targeted in the report:

•    What are the emerging trends in the global pharmacogenomics market? How are these trends revolutionizing the treatment procedure? 
•    Which technologies are anticipated to break-through the current pharmacogenomics regime?
•    Which companies are anticipated to be highly disruptive in the future and why?
•    What are the regulatory procedures that are required to unify the approval process for emerging pharmacogenomics? How will these enhance the reimbursement scenario?
•    What are the gaps in regularizing optimum pharmacogenomics adoption in regular healthcare routines? How are these gaps being tackled?

The key manufacturers who have been contributing significantly to the global pharmacogenomics market include Abbott Laboratories, F. Hoffmann-La Roche Ltd, Illumina, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics, Incorporated, Myriad Genetics, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., and Genomic Health, Inc., among others.

   1    Market Overview
         1.1    Introduction
         1.2    Market Definition
         1.3    Historical Perspective
         1.4    Significant Services in Pharmacogenomics
         1.5    Classification of Pharmacogenomics
         1.6    Global Footprint
         1.7    Future Potential
 
    2    Market Dynamics
          2.1    Overview
          2.2    Iceberg Analysis - Global Pharmacogenomics Market
          2.3    Impact Analysis
          2.4    Market Drivers
                   2.4.1    Increasing Prevalence of Infectious Diseases and Various Types of Cancer, Globally
                   2.4.2    Increase in Adoption of Personalized Medicine Shifting the Paradigm From Reaction to Prevention on a Global Level
                   2.4.3    Increasing Rate of Adverse Drug Reaction
                   2.4.4    Surge in Usage of Pharmacogenomics for Drug Discovery and Development
          2.5    Market Restraints
                   2.5.1    Lack of Use of Available Data for Drug Development Initiatives
                   2.5.2    Lack of High Complexity Testing Centers
                   2.5.3    Difficulties in Detecting Gene Variation Affecting Drug Response
          2.6    Market Opportunities
                   2.6.1    Massive Scope for Adoption of Pharmacogenomics in Emerging Nations
                   2.6.2    Technological Advancements in Molecular Techniques for Pharmacogenomic Diagnostic Tests
                   2.6.3    Rise of Direct-to-Consumer (DTC) Testing Services
 
    3    Competitive Landscape
          3.1    Key Strategies and Developments
                   3.1.1    Product Launches and Enhancements
                   3.1.2    Product Approvals
                   3.1.3    Synergistic Activities
                   3.1.4    Mergers and Acquisitions
                   3.1.5    Business Expansion Activities and Others
          3.2    Market Share Analysis
          3.3    Growth Share Analysis
          3.4    Industry Attractiveness
                   3.4.1    Bargaining Power of Suppliers
                   3.4.2    Bargaining Power of Buyers
                   3.4.3    Threat of New Entrants
                   3.4.4    Threat of Substitute Products
                   3.4.5    Intensity of Competitive Rivalry
 
    4    Regulatory Framework
          4.1    Legal Requirements and Framework in the U.S.
          4.2    Legal Requirements and Framework in Europe
          4.3    Legal Requirements and Framework in Asia-Pacific
                   4.3.1    China
                   4.3.2    Japan
          4.4    Patent Landscape
 
    5    Global Pharmacogenomics Market (by Service)
          5.1    Overview
          5.2    Genotyping
          5.3    SNP Identification
          5.4    Pharmacogenetic Testing
          5.5    Other Services
 
    6    Global Pharmacogenomics Market (by Application)
          6.1    Overview
          6.2    Oncology
          6.3    Infectious Diseases
          6.4    Neurology/Psychiatry
          6.5    Cardiovascular
          6.6    Other Applications
 
    7    Global Pharmacogenomics Market (by Technology)
          7.1    Overview
          7.2    Polymerase Chain Reaction (PCR)
          7.3    Microarray
          7.4    Sequencing
          7.5    Other Technologies
 
    8    Global Pharmacogenomics Market (by End User)
          8.1    Overview
          8.2    Research Organizations
                   8.2.1    Research Organizations (by Service)
          8.3    Pharmaceutical Companies
                   8.3.1    Pharmaceutical Companies (by Service)
          8.4    Diagnostic Centers
                   8.4.1    Diagnostics Centers (by Service)
          8.5    Other End Users
 
    9    Global Pharmacogenomics Market (by Region)
          9.1    Overview
          9.2    North America
                   9.2.1    The U.S.
                   9.2.2    Canada
                   9.2.3    North America Pharmacogenomics Market (by Application)
                   9.2.4    North America Pharmacogenomics Market (by Service)
          9.3    Europe
                   9.3.1    Germany
                   9.3.2    The U.K.
                   9.3.3    France
                   9.3.4    Italy
                   9.3.5    Spain
                   9.3.6    Denmark
                   9.3.7    The Netherlands
                   9.3.8    Rest-of-Europe
                   9.3.9    Europe Pharmacogenomics Market (by Application)
                   9.3.10    Europe Pharmacogenomics Market (by Service)
          9.4    Asia-Pacific
                   9.4.1    Japan
                   9.4.2    China
                   9.4.3    Australia
                   9.4.4    India
                   9.4.5    Singapore
                   9.4.6    Rest-of-APAC
                   9.4.7    Asia-Pacific Pharmacogenomics Market (by Application)
                   9.4.8    Asia-Pacific Pharmacogenomics Market (by Service)
          9.5    Latin America
                   9.5.1    Brazil
                   9.5.2    Mexico
                   9.5.3    Rest-of-Latin America
                   9.5.4    Latin America Pharmacogenomics Market (by Application)
                   9.5.5    Latin America Pharmacogenomics Market (by Service)
          9.6    Rest-of-the-World
                   9.6.1    RoW Pharmacogenomics Market (by Application)
                   9.6.2    RoW Pharmacogenomics Market (by Service)
 
    10    Company Profiles
            10.1    Overview
            10.2    Abbott Laboratories
                       10.2.1    Company Overview
                       10.2.2    Role of Abbott Laboratories in the Global Pharmacogenomics Market
                       10.2.3    Financials
                       10.2.4    Key Insights about Financial Health of the Company
                       10.2.5    SWOT Analysis
            10.3    Admera Health, LLC
                       10.3.1    Company Overview
                       10.3.2    Role of Admera Health, LLC in the Global Pharmacogenomics Market
                       10.3.3    SWOT Analysis
            10.4    Agena Biosciences, Inc.
                       10.4.1    Company Overview
                       10.4.2    Role of Agena Biosciences, Inc. in the Global Pharmacogenomics Market
                       10.4.3    SWOT Analysis
            10.5    Cancer Genetics, Inc.
                       10.5.1    Company Overview
                       10.5.2    Role of Cancer Genetics, Inc. in the Global Pharmacogenomics Market
                       10.5.3    Financials
                       10.5.4    Key Insights about Financial Health of the Company
                       10.5.5    SWOT Analysis
            10.6    Dynamic DNA Laboratories
                       10.6.1    Company Overview
                       10.6.2    Role of Dynamic DNA Laboratories in the Global Pharmacogenomics Market
                       10.6.3    SWOT Analysis
            10.7    F. Hoffmann-La Roche Ltd
                       10.7.1    Company Overview
                       10.7.2    Role of F. Hoffmann-La Roche Ltd in the Global Pharmacogenomics Market
                       10.7.3    Financials
                       10.7.4    Key Insights about Financial Health of the Company
                       10.7.5    SWOT Analysis
            10.8    geneOmbio Technologies Pvt Ltd.
                       10.8.1    Company Overview
                       10.8.2    Role of geneOmbio Technologies Pvt Ltd. in the Global Pharmacogenomics Market
                       10.8.3    SWOT Analysis
            10.9    Genomic Health, Inc.
                       10.9.1    Company Overview
                       10.9.2    Role of Genomic Health, Inc. in the Global Pharmacogenomics Market
                       10.9.3    Financials
                       10.9.4    Key Insights about Financial Health of the Company
                       10.9.5    SWOT Analysis
           10.10   Illumina, Inc.
                       10.10.1    Company Overview
                       10.10.2    Role of Illumina, Inc. in the Global Pharmacogenomics Market
                       10.10.3    Financials
                       10.10.4    Key Insights about Financial Health of the Company
                       10.10.5    SWOT Analysis
            10.11   Laboratory Corporation of America Holdings
                       10.11.1    Company Overview
                       10.11.2    Role of Laboratory Corporation of America Holdings in the Global Pharmacogenomics Market
                       10.11.3    Financials
                       10.11.4    SWOT Analysis
           10.12   Myriad Genetics, Inc.
                       10.12.1    Company Overview
                       10.12.2    Role of Myriad Genetics, Inc. in the Global Pharmacogenomics Market
                       10.12.3    Financials
                       10.12.4    SWOT Analysis
           10.13   Pathway Genomics Corporation
                       10.13.1    Company Overview
                       10.13.2    Role of Pathway Genomics Corporation in the Global Pharmacogenomics Market
                       10.13.3    SWOT Analysis
           10.14   QIAGEN N.V.
                       10.14.1    Company Overview
                       10.14.2    Role of QIAGEN N.V. in the Global Pharmacogenomics Market
                       10.14.3    Financials
                       10.14.4    Key Insights about Financial Health of the Company
                       10.14.5    SWOT Analysis
           10.15   Quest Diagnostics Incorporated
                       10.15.1    Company Overview
                       10.15.2    Role of Quest Diagnostics Incorporated in the Global   Pharmacogenomics Market
                       10.15.3    Financials
                       10.15.4    SWOT Analysis
           10.16   Thermo Fisher Scientific Inc.
                       10.16.1    Company Overview
                       10.16.2    Role of Thermo Fisher Scientific Inc. in the Global Pharmacogenomics Market
                       10.16.3    Financials
                       10.16.4    Key Insights about Financial Health of the Company
                       10.16.5    SWOT Analysis
           10.17   Transgenomic, Inc.
                       10.17.1    Company Overview
                       10.17.2    Role of Transgenomic, Inc. in the Global Pharmacogenomics Market
                       10.17.3    SWOT Analysis
           10.18   23andMe, Inc.
                       10.18.1    Company Overview
                       10.18.2    Role of 23andMe, Inc. in the Global Pharmacogenomics Market
           10.19   OneOme, LLC
                       10.19.1    Company Overview
                       10.19.2    Role of OneOme, LLC in the Global Pharmacogenomics Market
           10.20   Astra Zeneca PLC
                       10.20.1    Company Overview
                       10.20.2    Role of Astra Zeneca PLC in the Global Pharmacogenomics Market
 
    11    Research Scope and Methodology
            11.1    Research Scope
            11.2    Global Pharmacogenomics Market: Research Methodology
 

List of Tables

Table 2.1:    Impact Analysis of Market Drivers
Table 2.2:    Impact Analysis of Market Restraints
Table 2.3:    Examples of Adverse Drug Reactions
Table 4.1:    Classification rules of IVDs under the IVDR
Table 4.2:    Registration Criteria for IVD Medical Devices as per the CFDA

List of Figures

Figure 1:    Estimates for Global Healthcare Market, 2018 and 2020
Figure 2:    Impact of Market Drivers and Market Restraints on the Global Pharmacogenomics Market
Figure 3:    Global Pharmacogenomics Market Snapshot (in $Million)
Figure 4:    Dominating Segments of the Global Pharmacogenomics Market, 2018 and 2028
Figure 5:    Global Pharmacogenomics Market (by Service), 2018 and 2028
Figure 6:    Global Pharmacogenomics Market (by Application), 2018 and 2028
Figure 7:    Global Pharmacogenomics Market (by Technology), 2018 and 2028
Figure 8:    Global Pharmacogenomics Market (by End User), 2018 and 2028
Figure 9:    Global Pharmacogenomics Market (by Region), 2018 and 2028
Figure 1.1:    Evolution of Pharmacogenomics
Figure 1.2:    Classification of Pharmacogenomics
Figure 1.3:    Global Pharmacogenomics (PGx) Market, 2018-2028
Figure 2.1:    Iceberg Analysis - Global Pharmacogenomics Market
Figure 2.2:    Number of Deaths by Top 18 Infectious Diseases, 2015
Figure 2.3:    Number of Deaths (in Millions) by Different Forms of Cancer, 2018
Figure 2.4:    Benefits of Multiplexing Reactions
Figure 3.1:    Share of Key Developments and Strategies, January 2016 – April 2019
Figure 3.2:    Product Launches Share (by Company), January 2016 – April 2019
Figure 3.3:    Product Approvals Share (by Company), January 2016 – April 2019
Figure 3 4:    Synergistic Activities Share (by Company), January 2016 – April 2019
Figure 3.5:    Market Share Analysis for the Global Pharmacogenomics Market, 2017
Figure 3.6:    Market Share Analysis for the Global Pharmacogenomics Market, 2018
Figure 3.7:    Growth Share Matrix for Global Pharmacogenomics Market (by Companies), 2018
Figure 3.8:    Overall Industry Attractiveness, 2018 and 2028
Figure 3.9:    Overall Impact of Bargaining Power of Suppliers
Figure 3.10:    Overall Impact of Bargaining Power of Buyers
Figure 3.11:    Overall Impact of Threat of New Entrants
Figure 3.12:    Overall Impact of Threat of Substitute Products
Figure 3.13:    Overall Impact of Intensity of Competitive Rivalry
Figure 4.1:    Components Considered for Clinical Evidence as per the IVDR
Figure 4.2:    Process of Medical Device Designation by the MHLW and PMDA
Figure 4.3:    Share of Patents (by Ownership), 2016-2019
Figure 5.1:    Global Pharmacogenomics Market (by Service)
Figure 5.2:    Global Pharmacogenomics Market (by Service), 2018 and 2028
Figure 5.3:    Global Pharmacogenomics Market (by Genotyping Service), 2018-2028
Figure 5.4:    Global Pharmacogenomics Market (by SNP Identification Service), 2018-2028
Figure 5.5:    Global Pharmacogenomics Market (by Pharmacogenetic Testing Service), 2018-2028
Figure 5.6:    Global Pharmacogenomics Market (by Other Testing Services), 2018-2028
Figure 6.1:    Global Pharmacogenomics Market (by Application)
Figure 6.2:    Global Pharmacogenomics Market (by Application), 2018 and 2028
Figure 6.3:    Global Pharmacogenomics Market (by Oncology), 2018-2028
Figure 6.4:    Global Pharmacogenomics Market (by Infectious Diseases), 2018-2028
Figure 6.5:    Global Pharmacogenomics Market (by Neurology/Psychiatry), 2018-2028
Figure 6.6:    Global Pharmacogenomics Market (by Cardiovascular), 2018-2028
Figure 6.7:    Global Pharmacogenomics Market (by Other Applications), 2018-2028
Figure 7.1:    Global Pharmacogenomics Market (by Technology)
Figure 7.2:    Global Pharmacogenomics Market (by Technology), 2018 and 2028
Figure 7.3:    Global Pharmacogenomics Market (by PCR), 2018-2028
Figure 7.4:    Global Pharmacogenomics Market (by Microarray), 2018-2028
Figure 7.5:    Evolution of Sequencing for Molecular Diagnostics
Figure 7.6:    Global Pharmacogenomics Market (by Sequencing), 2018-2028
Figure 7.7:    Global Pharmacogenomics Market (by Other Technologies), 2018-2028
Figure 8.1:    Global Pharmacogenomics Market (by End User)
Figure 8.2:    Global Pharmacogenomics Market (by End User), 2018 and 2028
Figure 8.3:    Global Pharmacogenomics Market (by Research Organizations), 2018-2028
Figure 8.4:    Research Organizations (by Service), Share 2018 and 2028
Figure 8.5:    Global Pharmacogenomics Market (by Pharmaceutical Companies), 2018-2028
Figure 8.6:    Pharmaceutical Companies (by Service), 2018 and 2028
Figure 8.7:    Global Pharmacogenomics Market (by Diagnostic Centers), 2018-2028
Figure 8.8:    Diagnostics Centers (by Service), 2018 and 2028
Figure 8.9:    Global Pharmacogenomics Market (by Other End Users), 2018-2028
Figure 9.1:    Global Pharmacogenomics Market (by Region), 2018 and 2028
Figure 9.2:    Global Pharmacogenomics Market (by Region), 2018-2028
Figure 9.3:    Global Pharmacogenomics Market Share (by Region), 2018
Figure 9.4:    Global Pharmacogenomics Market Share (by Region), 2028
Figure 9.5:    North America Pharmacogenomics Market, 2018-2028
Figure 9.6:    North America: Market Dynamics
Figure 9.7:    North America Pharmacogenomics Market (by Country), 2018-2028
Figure 9.8:    The U.S. Pharmacogenomics Market, 2018-2028
Figure 9.9:    Canada Pharmacogenomics Market, 2018-2028
Figure 9.10:    North America Pharmacogenomics Market (by Application), 2018 and 2028
Figure 9.11:    North America Pharmacogenomics Market (by Service), 2018 and 2028
Figure 9.12:    Europe Pharmacogenomics Market, 2018-2028
Figure 9.13:    Europe: Market Dynamics
Figure 9.14:    Europe Pharmacogenomics Market (by Country), 2018-2028
Figure 9.15:    Germany Pharmacogenomics Market, 2018-2028
Figure 9.16:    The U.K. Pharmacogenomics Market, 2018-2028
Figure 9.17:    France Pharmacogenomics Market, 2018-2028
Figure 9.18:    Italy Pharmacogenomics Market, 2018-2028
Figure 9 19:    Spain Pharmacogenomics Market, 2018-2028
Figure 9 20:    Denmark Pharmacogenomics Market, 2018-2028
Figure 9.21:    The Netherlands Pharmacogenomics Market, 2018-2028
Figure 9.22:    Rest-of-Europe Pharmacogenomics Market, 2018-2028
Figure 9.23:    Europe Pharmacogenomics Market (by Application), 2018 and 2028
Figure 9.24:    Europe Pharmacogenomics Market (by Service), 2018 and 2028
Figure 9.25:    Asia-Pacific Pharmacogenomics Market, 2018-2028
Figure 9.26:    APAC: Market Dynamics
Figure 9.27:    APAC Pharmacogenomics Market (by Country), 2018-2028
Figure 9.28:    Japan Pharmacogenomics Market, 2018-2028
Figure 9.29:    China Pharmacogenomics Market, 2018-2028
Figure 9.30:    Australia Pharmacogenomics Market, 2018-2028
Figure 9.31:    India Pharmacogenomics Market, 2018-2028
Figure 9.32:    Singapore Pharmacogenomics Market, 2018-2028
Figure 9.33:    RoAPAC Pharmacogenomics Market, 2018-2028
Figure 9.34:    Asia-Pacific Pharmacogenomics Market (by Application), 2018 and 2028
Figure 9.35:    Asia-Pacific Pharmacogenomics Market (by Service), 2018 and 2028
Figure 9.36:    Latin America Pharmacogenomics Market, 2018-2028
Figure 9.37:    Latin America: Market Dynamics
Figure 9.38:    Latin America Pharmacogenomics Market (by Country), 2018-2028
Figure 9.39:    Brazil Pharmacogenomics Market, 2018-2028
Figure 9.40:    Mexico Pharmacogenomics Market, 2018-2028
Figure 9.41:    Rest-of-Latin America Pharmacogenomics Market, 2018-2028
Figure 9.42:    Latin America Pharmacogenomics Market (by Application), 2018 and 2028
Figure 9.43:    Latin America Pharmacogenomics Market (by Service), 2018 and 2028
Figure 9.44:    RoW Pharmacogenomics Market, 2018-2028
Figure 9.45:    RoW Pharmacogenomics Market (by Application), 2018 and 2028
Figure 9.46:    RoW Pharmacogenomics Market (by Service), 2018 and 2028
Figure 10.1:    Total Number of Companies Profiled
Figure 10.2:    Abbott Laboratories: Overall Product Portfolio
Figure 10.3:    Abbott Laboratories: Overall Financials, 2016-2018
Figure 10.4:    Abbott Laboratories: Revenue (by Segment), 2016-2018
Figure 10.5:    Abbott Laboratories: Revenue Split for Diagnostics, 2016-2018
Figure 10.6:    Abbott Laboratories: Revenue (by Region), 2016-2018
Figure 10.7:    Abbott Laboratories: R&D Expenditure, 2016-2018
Figure 10.8:    Abbott Laboratories: SWOT Analysis
Figure 10.9:    Admera Health, LLC: Overall Product Portfolio
Figure 10.10:    Admera Health, LLC: SWOT Analysis
Figure 10.11:    Agena Biosciences, Inc.: Overall Product Portfolio
Figure 10.12:    Agena Biosciences, Inc.: SWOT Analysis
Figure 10.13:    Product Portfolio: Cancer Genetics, Inc.
Figure 10.14:    Cancer Genetics, Inc.: Overall Financials, 2016-2018
Figure 10.15:    Cancer Genetics, Inc.: Revenue (by Segment), 2016-2018
Figure 10.16:    Cancer Genetics, Inc.: R&D Expenditure, 2016-2018
Figure 10.17:    Cancer Genetics, Inc.: SWOT Analysis
Figure 10.18:    Dynamic DNA Laboratories: Overall Product Portfolio
Figure 10.19:    Dynamic DNA Laboratories: SWOT Analysis
Figure 10.20:    F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 10.21:    F. Hoffmann-La Roche Ltd: Overall Financials, 2016-2018
Figure 10.22:    F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2016-2018
Figure 10.23:    F. Hoffmann-La Roche Ltd: Revenue Split for Diagnostics, 2016-2018
Figure 10.24:    F. Hoffmann-La Roche Ltd: Revenue (by Region), 2016-2018
Figure 10.25:    F. Hoffmann-La Roche Ltd: R&D Expenditure, 2016-2018
Figure 10.26:    F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 10.27:    geneOmbio Technologies Pvt Ltd.: Overall Product Portfolio
Figure 10.28:    geneOmbio Technologies Pvt Ltd.: SWOT Analysis
Figure 10.29:    Genomic Health, Inc.: Overall Product Portfolio
Figure 10.30:    Genomic Health, Inc.: Overall Financials, 2016-2018
Figure 10.31:    Genomic Health, Inc.: Revenue (by Segment), 2016-2018
Figure 10.32:    Genomic Health, Inc.: Revenue (by Region), 2016-2018
Figure 10.33:    Genomic Health, Inc.: R&D Expenditure, 2016-2018
Figure 10.34:    Genomic Health, Inc.: SWOT Analysis
Figure 10.35:    Illumina, Inc.: Overall Product Portfolio
Figure 10.36:    Illumina, Inc.: Overall Financials, 2016-2018
Figure 10.37:    Illumina, Inc.: Revenue (by Segment), 2016-2018
Figure 10.38:    Illumina, Inc.: Revenue (by Region), 2016-2018
Figure 10.39:    Illumina, Inc.: R&D Expenditure, 2016-2018
Figure 10.40:    Illumina, Inc.: SWOT Analysis
Figure 10.41:    Laboratory Corporation of America Holdings: Overall Product Portfolio
Figure 10.42:    Laboratory Corporation of America Holdings: Overall Financials, 2016-2018
Figure 10.43:    Laboratory Corporation of America Holdings: Revenue (by Segment), 2016-2018
Figure 10.44:    Laboratory Corporation of America Holdings: Revenue (by Region), 2018
Figure 10.45:    Laboratory Corporation of America Holdings: SWOT Analysis
Figure 10.46:    Myriad Genetics, Inc.: Overall Product Portfolio
Figure 10.47:    Myriad Genetics, Inc.: Overall Financials, 2016-2018
Figure 10.48:    Myriad Genetics, Inc.: Revenue (by Business Segment), 2016-2018
Figure 10.49:    Myriad Genetics, Inc.: SWOT Analysis
Figure 10.50:    Pathway Genomics Corporation: Overall Product Portfolio
Figure 10.51:    Pathway Genomics Corporation: SWOT Analysis
Figure 10.52:    QIAGEN N.V.: Overall Product Portfolio
Figure 10.53:    QIAGEN N.V.: Overall Financials, 2016-2018
Figure 10.54:    QIAGEN N.V.: Revenue (by Segment), 2016-2018
Figure 10.55:    QIAGEN N.V.: Revenue (by Region), 2016-2018
Figure 10.56:    QIAGEN N.V.: R&D Expenditure, 2016-2018
Figure 10.57:    QIAGEN N.V.: SWOT Analysis
Figure 10.58:    Product Portfolio: Quest Diagnostics Incorporated
Figure 10.59:    Quest Diagnostics Incorporated: Overall Financials, 2016-2018
Figure 10.60:    Quest Diagnostics Incorporated: Revenue (by Segment), 2016-2018
Figure 10.61:    Quest Diagnostics Incorporated: SWOT Analysis
Figure 10.62:    Thermo Fisher Scientific Inc.: Overall Product Portfolio
Figure 10.63:    Thermo Fisher Scientific Inc.: Overall Financials, 2016-2018
Figure 10.64:    Thermo Fisher Scientific Inc.: Revenue (by Segment), 2016-2018
Figure 10.65:    Thermo Fisher Scientific Inc.: Revenue (by Region), 2016-2018
Figure 10.66:    Thermo Fisher Scientific Inc.: R&D Expenditure, 2016-2018
Figure 10.67:    Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 10.68:    Transgenomic, Inc.: Overall Product Portfolio
Figure 10.69:    Transgenomic, Inc.: SWOT Analysis
Figure 10.70:    23and Me, Inc.: Overall Product Portfolio
Figure 10.71:    OneOme, LLC: Overall Product Portfolio
Figure 11.1:    Global Pharmacogenomics Market Segmentation
Figure 11.2:    Global Pharmacogenomics Market Research Methodology
Figure 11.3:    Primary Research
Figure 11.4:    Secondary Research
Figure 11.5:    Data Triangulation
Figure 11.6:    Bottom-up Approach (Segment-wise Analysis)
Figure 11.7:    Top-down Approach (Segment-wise Analysis)
Figure 11.8:    Assumptions and Limitations
Figure 11.9:    Considered Factors for Data Prediction and Modeling

As World Health Organization states, the global healthcare expenditure is on the course to be an exorbitant $8.5 trillion in 2020, owing to an increasing economic burden of chronic diseases, which are estimated to constitute almost 43% of the global economic burden. Thus, the escalating demand for better treatment outcome is leading to an ascending need for preventive, precise healthcare, and tailored medication. The growth of the precision medicine market over the last few years (2010-2017) has been colossal and has significantly contributed to giving rise to a number of parallel fields of study and possible healthcare implementations. Pharmacogenomics is defined as the study of the whole genome with respect to drug response, is consistently revolutionizing healthcare at the interface of precision medicine, with implications for drug development in order to provide superior treatment. 

The rapid growth of clinically relevant pharmacogenomic knowledge and drugs used for patient treatment in virtually every medical specialty, is consistently aiding in the evolution of prevention-based treatment. With a critical role in the global precision medicine phenomenon, pharmacogenomics is responsible for ensuring safe and effective application of targeted therapeutics. The services offered by the major players in the pharmacogenomics market encompass categories such as genotyping, single nucleotide polymorphism (SNP) identification, and pharmacogenetic testing, among others. Also, several diagnostics and pharmaceutical companies are presently undertaking synergistic activities for the development of NGS-, PCR-, IHC-, ISH-, microarray-, or mass spectrometry-based pharmacogenomics for the applications in several disease indications, in order to enable efficient diagnosis, treatment selection, dosage selection, and treatment monitoring. The applications of pharmacogenomics primarily include oncology, infectious diseases, neurology/psychiatry, and cardiovascular, among others. Aside from the discovery of effective biomarkers for the development of efficient pharmacogenomics kits, obtaining regulatory approval is essential. The efficiency and effectiveness primarily depend upon the approval of a pharmacogenomics in the stratification of the patient population as responders and non-responders to aid in the selection of appropriate treatment. Therefore, the entire regulatory and approval process necessitates close collaboration between the manufacturer of the targeted drug and the manufacturer of corresponding genetic test. Besides research organizations, pharmaceutical companies, and diagnostic centers, among others, are also prominent end users of pharmacogenomics.

This growth has been primarily attributed to the major drivers in this market such as a highly increasing prevalence of infectious diseases and various types of cancer globally, increase in adoption of personalized medicine shifting the paradigm from reaction to prevention on a global level, increasing rate of adverse drug reaction, and surge in usage of pharmacogenomics for drug discovery and development. These individualized care regimes are improving quality of life of the patients and reducing economic, societal, and clinical burden, projecting a future of prosperity.

Presently, service categories within the pharmacogenomics market include genotyping, SNP identification, and pharmacogenetic testing. Till date, the healthcare industry has witnessed a number of successful products and services that have contributed significantly to the enhancement of technological advancements in making treatment more precise. As of 2018, pharmacogenomics, though minimally reimbursed, can be seen to have large-scale exposure in almost all the developed countries. However, with the rapid advancements taking place and an exponential progression in the number of companies entering the space, access to consumers is bound to become easier, thus significantly increasing the exposure in less-developed countries. The global pharmacogenomics market has been witnessing a steady growth since the end of the Human Genome Project in 2003. The market is expected to continue to grow with a double digit CAGR of 6.98% during the forecast period, 2019-2028. Growing at a CAGR of 6.42% during the forecast period of 2019-2028, the genotyping service segment is anticipated to generate a value of $3.54 billion in 2028. However, the global market for pharmacogenetic testing services is anticipated to grow at the fastest CAGR of 8.95% during the forecast period 2019-2028.

The purpose of the study is to gain a holistic view of the global pharmacogenomics market in terms of various factors influencing the same, including regulatory reforms, and technological advancements. The market has been segmented into ‘services’, ‘applications’, ‘technologies’, ‘end users’, and ‘regions’. The scope of this report is centered upon conducting a detailed study of the products and services allied with the pharmacogenomics market. In addition, the study also includes the exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each service, application, technology, end user, region, and company, as well as other vital information with respect to global pharmacogenomics market.

Based on the region, the global pharmacogenomics market is segmented into North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World (RoW). North America is the leading contributor to the global pharmacogenomics market and was responsible for a 50.89% share of the global market values in 2018. However, the Asia-Pacific region is expected to grow at the fastest pace among all other regions with a CAGR of 8.82% during the forecast period 2019-2028.

The key players who have been contributing significantly to the global pharmacogenomics market include Abbott Laboratories, F. Hoffmann-La Roche Ltd, Illumina, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics, Incorporated, Myriad Genetics, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., and Genomic Health, Inc., among others.

We understand that your business need specific answers pertaining to the market. And , therefore, we do provide customised research tailored to your need.

With the purchase of this report, you are entitled to certain degree of free customisation within the scope of the study.

Do get in touch to help us understand how we can serve u better with a custom solution to your research needs. We assure quick turnaround for your pressing business requirements.

Contact Information


Name *
Email *
 
Company Name *
Designation*
 
 
Contact No. *
Other Details
 
 

Write the characters in the image above
 
 
* Required Fields

REQUEST SAMPLE   Schedule A Call
PLEASE SELECT A LICENSE TYPE
 
 
 

  REQUEST    SAMPLE   Schedule
    A Call

Pharmacogenomic services have significantly transformed the entire medical industry. With evolution of these services into direct-to-consumer tests, the global scope has been expanded to cover the entire healthcare gamut, further personalizing treatment modules. The rapid growth of clinically relevant pharmacogenomic knowledge and drugs used for patient treatment in virtually every medical specialty, is consistently aiding in the evolution of prevention-based treatment. With a critical role in the global precision medicine phenomenon, pharmacogenomics is responsible for ensuring safe and effective application of targeted therapeutics. These individualized care regimes are improving the quality of life of the patients and reducing economic, societal, and clinical burden, projecting a future of prosperity. 

Presently, service categories within the pharmacogenomics market include genotyping, SNP identification, and pharmacogenetic testing, among others. Although services are widespread, there is still considerable apprehension toward the adoption of genetic testing services in order to stratify patients for drug selection and dosage. Minimal reimbursement in developed countries such as the U.S., though restraining growth in the market, is being overcome by an increasing patient awareness that is leading to growth in the market.

The purpose of the study is to gain a holistic view of the global pharmacogenomics market in terms of various factors influencing it, including regulatory reforms, and technological advancements. The market has been segmented into ‘services’, ‘applications’, ‘technologies’, ‘end users’, and ‘regions’. The scope of this report is centered upon conducting a detailed study of the products and services allied with the pharmacogenomics market. In addition, the study also includes the exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each service, application, technology, end user, region, and company, as well as other vital information with respect to global pharmacogenomics market. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.

This research report aims at answering various aspects of the global pharmacogenomics market with the help of the key factors driving the market, the restraints, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.

The research study highlights the factors governing the industry attractiveness with Porter’s Five Forces for a comprehensive understanding of the global pharmacogenomics market. Moreover, the study includes detailed product mapping, market estimation, and analysis of key trends in multiple geographical regions, growth of pharmacogenomics market in each region for different applications, and the key strategies and developments by the prominent pharmacogenomics manufacturers and service providers.

The answers to the following key questions can be derived from this report:

•    What are the major market drivers, challenges, and opportunities in the global pharmacogenomics market?
•    What are the underlying structures resulting in the emerging trends within the global pharmacogenomics market?
•    How will each segment of the global pharmacogenomics market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2028?
•    What are the key developmental strategies which are implemented by the major players in order to sustain in the competitive market? What are the key regulatory implications in developed and developing regions for pharmacogenomics?
•    Who are the leading players with significant offerings to the global pharmacogenomics market? What is the current market dominance for each of these leading players?
•    What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2019-2028? Which pharmacogenomics service type is estimated to witness the most promising growth? 
•    What are the key applications in global pharmacogenomics market? What are the major segments of these applications? 
•    What are the major technologies that are employed in the global pharmacogenomics market? Which is the dominating technology?
•    Who are the primary end users of the global pharmacogenomics market? Which is the fastest growing end use segment in the global pharmacogenomics market? What are the services that are being provided by these end users?
•    Who are the key manufacturers and service providers in the global pharmacogenomics market, and what are their contributions? Also, what is the growth potential of each major pharmacogenomics manufacturer and service provider?
•    What is the scope of the global pharmacogenomics market in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World? Which pharmacogenomics application and service type dominate these regions?

Key trends targeted in the report:

•    What are the emerging trends in the global pharmacogenomics market? How are these trends revolutionizing the treatment procedure? 
•    Which technologies are anticipated to break-through the current pharmacogenomics regime?
•    Which companies are anticipated to be highly disruptive in the future and why?
•    What are the regulatory procedures that are required to unify the approval process for emerging pharmacogenomics? How will these enhance the reimbursement scenario?
•    What are the gaps in regularizing optimum pharmacogenomics adoption in regular healthcare routines? How are these gaps being tackled?

The key manufacturers who have been contributing significantly to the global pharmacogenomics market include Abbott Laboratories, F. Hoffmann-La Roche Ltd, Illumina, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics, Incorporated, Myriad Genetics, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., and Genomic Health, Inc., among others.

   1    Market Overview
         1.1    Introduction
         1.2    Market Definition
         1.3    Historical Perspective
         1.4    Significant Services in Pharmacogenomics
         1.5    Classification of Pharmacogenomics
         1.6    Global Footprint
         1.7    Future Potential
 
    2    Market Dynamics
          2.1    Overview
          2.2    Iceberg Analysis - Global Pharmacogenomics Market
          2.3    Impact Analysis
          2.4    Market Drivers
                   2.4.1    Increasing Prevalence of Infectious Diseases and Various Types of Cancer, Globally
                   2.4.2    Increase in Adoption of Personalized Medicine Shifting the Paradigm From Reaction to Prevention on a Global Level
                   2.4.3    Increasing Rate of Adverse Drug Reaction
                   2.4.4    Surge in Usage of Pharmacogenomics for Drug Discovery and Development
          2.5    Market Restraints
                   2.5.1    Lack of Use of Available Data for Drug Development Initiatives
                   2.5.2    Lack of High Complexity Testing Centers
                   2.5.3    Difficulties in Detecting Gene Variation Affecting Drug Response
          2.6    Market Opportunities
                   2.6.1    Massive Scope for Adoption of Pharmacogenomics in Emerging Nations
                   2.6.2    Technological Advancements in Molecular Techniques for Pharmacogenomic Diagnostic Tests
                   2.6.3    Rise of Direct-to-Consumer (DTC) Testing Services
 
    3    Competitive Landscape
          3.1    Key Strategies and Developments
                   3.1.1    Product Launches and Enhancements
                   3.1.2    Product Approvals
                   3.1.3    Synergistic Activities
                   3.1.4    Mergers and Acquisitions
                   3.1.5    Business Expansion Activities and Others
          3.2    Market Share Analysis
          3.3    Growth Share Analysis
          3.4    Industry Attractiveness
                   3.4.1    Bargaining Power of Suppliers
                   3.4.2    Bargaining Power of Buyers
                   3.4.3    Threat of New Entrants
                   3.4.4    Threat of Substitute Products
                   3.4.5    Intensity of Competitive Rivalry
 
    4    Regulatory Framework
          4.1    Legal Requirements and Framework in the U.S.
          4.2    Legal Requirements and Framework in Europe
          4.3    Legal Requirements and Framework in Asia-Pacific
                   4.3.1    China
                   4.3.2    Japan
          4.4    Patent Landscape
 
    5    Global Pharmacogenomics Market (by Service)
          5.1    Overview
          5.2    Genotyping
          5.3    SNP Identification
          5.4    Pharmacogenetic Testing
          5.5    Other Services
 
    6    Global Pharmacogenomics Market (by Application)
          6.1    Overview
          6.2    Oncology
          6.3    Infectious Diseases
          6.4    Neurology/Psychiatry
          6.5    Cardiovascular
          6.6    Other Applications
 
    7    Global Pharmacogenomics Market (by Technology)
          7.1    Overview
          7.2    Polymerase Chain Reaction (PCR)
          7.3    Microarray
          7.4    Sequencing
          7.5    Other Technologies
 
    8    Global Pharmacogenomics Market (by End User)
          8.1    Overview
          8.2    Research Organizations
                   8.2.1    Research Organizations (by Service)
          8.3    Pharmaceutical Companies
                   8.3.1    Pharmaceutical Companies (by Service)
          8.4    Diagnostic Centers
                   8.4.1    Diagnostics Centers (by Service)
          8.5    Other End Users
 
    9    Global Pharmacogenomics Market (by Region)
          9.1    Overview
          9.2    North America
                   9.2.1    The U.S.
                   9.2.2    Canada
                   9.2.3    North America Pharmacogenomics Market (by Application)
                   9.2.4    North America Pharmacogenomics Market (by Service)
          9.3    Europe
                   9.3.1    Germany
                   9.3.2    The U.K.
                   9.3.3    France
                   9.3.4    Italy
                   9.3.5    Spain
                   9.3.6    Denmark
                   9.3.7    The Netherlands
                   9.3.8    Rest-of-Europe
                   9.3.9    Europe Pharmacogenomics Market (by Application)
                   9.3.10    Europe Pharmacogenomics Market (by Service)
          9.4    Asia-Pacific
                   9.4.1    Japan
                   9.4.2    China
                   9.4.3    Australia
                   9.4.4    India
                   9.4.5    Singapore
                   9.4.6    Rest-of-APAC
                   9.4.7    Asia-Pacific Pharmacogenomics Market (by Application)
                   9.4.8    Asia-Pacific Pharmacogenomics Market (by Service)
          9.5    Latin America
                   9.5.1    Brazil
                   9.5.2    Mexico
                   9.5.3    Rest-of-Latin America
                   9.5.4    Latin America Pharmacogenomics Market (by Application)
                   9.5.5    Latin America Pharmacogenomics Market (by Service)
          9.6    Rest-of-the-World
                   9.6.1    RoW Pharmacogenomics Market (by Application)
                   9.6.2    RoW Pharmacogenomics Market (by Service)
 
    10    Company Profiles
            10.1    Overview
            10.2    Abbott Laboratories
                       10.2.1    Company Overview
                       10.2.2    Role of Abbott Laboratories in the Global Pharmacogenomics Market
                       10.2.3    Financials
                       10.2.4    Key Insights about Financial Health of the Company
                       10.2.5    SWOT Analysis
            10.3    Admera Health, LLC
                       10.3.1    Company Overview
                       10.3.2    Role of Admera Health, LLC in the Global Pharmacogenomics Market
                       10.3.3    SWOT Analysis
            10.4    Agena Biosciences, Inc.
                       10.4.1    Company Overview
                       10.4.2    Role of Agena Biosciences, Inc. in the Global Pharmacogenomics Market
                       10.4.3    SWOT Analysis
            10.5    Cancer Genetics, Inc.
                       10.5.1    Company Overview
                       10.5.2    Role of Cancer Genetics, Inc. in the Global Pharmacogenomics Market
                       10.5.3    Financials
                       10.5.4    Key Insights about Financial Health of the Company
                       10.5.5    SWOT Analysis
            10.6    Dynamic DNA Laboratories
                       10.6.1    Company Overview
                       10.6.2    Role of Dynamic DNA Laboratories in the Global Pharmacogenomics Market
                       10.6.3    SWOT Analysis
            10.7    F. Hoffmann-La Roche Ltd
                       10.7.1    Company Overview
                       10.7.2    Role of F. Hoffmann-La Roche Ltd in the Global Pharmacogenomics Market
                       10.7.3    Financials
                       10.7.4    Key Insights about Financial Health of the Company
                       10.7.5    SWOT Analysis
            10.8    geneOmbio Technologies Pvt Ltd.
                       10.8.1    Company Overview
                       10.8.2    Role of geneOmbio Technologies Pvt Ltd. in the Global Pharmacogenomics Market
                       10.8.3    SWOT Analysis
            10.9    Genomic Health, Inc.
                       10.9.1    Company Overview
                       10.9.2    Role of Genomic Health, Inc. in the Global Pharmacogenomics Market
                       10.9.3    Financials
                       10.9.4    Key Insights about Financial Health of the Company
                       10.9.5    SWOT Analysis
           10.10   Illumina, Inc.
                       10.10.1    Company Overview
                       10.10.2    Role of Illumina, Inc. in the Global Pharmacogenomics Market
                       10.10.3    Financials
                       10.10.4    Key Insights about Financial Health of the Company
                       10.10.5    SWOT Analysis
            10.11   Laboratory Corporation of America Holdings
                       10.11.1    Company Overview
                       10.11.2    Role of Laboratory Corporation of America Holdings in the Global Pharmacogenomics Market
                       10.11.3    Financials
                       10.11.4    SWOT Analysis
           10.12   Myriad Genetics, Inc.
                       10.12.1    Company Overview
                       10.12.2    Role of Myriad Genetics, Inc. in the Global Pharmacogenomics Market
                       10.12.3    Financials
                       10.12.4    SWOT Analysis
           10.13   Pathway Genomics Corporation
                       10.13.1    Company Overview
                       10.13.2    Role of Pathway Genomics Corporation in the Global Pharmacogenomics Market
                       10.13.3    SWOT Analysis
           10.14   QIAGEN N.V.
                       10.14.1    Company Overview
                       10.14.2    Role of QIAGEN N.V. in the Global Pharmacogenomics Market
                       10.14.3    Financials
                       10.14.4    Key Insights about Financial Health of the Company
                       10.14.5    SWOT Analysis
           10.15   Quest Diagnostics Incorporated
                       10.15.1    Company Overview
                       10.15.2    Role of Quest Diagnostics Incorporated in the Global   Pharmacogenomics Market
                       10.15.3    Financials
                       10.15.4    SWOT Analysis
           10.16   Thermo Fisher Scientific Inc.
                       10.16.1    Company Overview
                       10.16.2    Role of Thermo Fisher Scientific Inc. in the Global Pharmacogenomics Market
                       10.16.3    Financials
                       10.16.4    Key Insights about Financial Health of the Company
                       10.16.5    SWOT Analysis
           10.17   Transgenomic, Inc.
                       10.17.1    Company Overview
                       10.17.2    Role of Transgenomic, Inc. in the Global Pharmacogenomics Market
                       10.17.3    SWOT Analysis
           10.18   23andMe, Inc.
                       10.18.1    Company Overview
                       10.18.2    Role of 23andMe, Inc. in the Global Pharmacogenomics Market
           10.19   OneOme, LLC
                       10.19.1    Company Overview
                       10.19.2    Role of OneOme, LLC in the Global Pharmacogenomics Market
           10.20   Astra Zeneca PLC
                       10.20.1    Company Overview
                       10.20.2    Role of Astra Zeneca PLC in the Global Pharmacogenomics Market
 
    11    Research Scope and Methodology
            11.1    Research Scope
            11.2    Global Pharmacogenomics Market: Research Methodology
 

List of Tables

Table 2.1:    Impact Analysis of Market Drivers
Table 2.2:    Impact Analysis of Market Restraints
Table 2.3:    Examples of Adverse Drug Reactions
Table 4.1:    Classification rules of IVDs under the IVDR
Table 4.2:    Registration Criteria for IVD Medical Devices as per the CFDA

List of Figures

Figure 1:    Estimates for Global Healthcare Market, 2018 and 2020
Figure 2:    Impact of Market Drivers and Market Restraints on the Global Pharmacogenomics Market
Figure 3:    Global Pharmacogenomics Market Snapshot (in $Million)
Figure 4:    Dominating Segments of the Global Pharmacogenomics Market, 2018 and 2028
Figure 5:    Global Pharmacogenomics Market (by Service), 2018 and 2028
Figure 6:    Global Pharmacogenomics Market (by Application), 2018 and 2028
Figure 7:    Global Pharmacogenomics Market (by Technology), 2018 and 2028
Figure 8:    Global Pharmacogenomics Market (by End User), 2018 and 2028
Figure 9:    Global Pharmacogenomics Market (by Region), 2018 and 2028
Figure 1.1:    Evolution of Pharmacogenomics
Figure 1.2:    Classification of Pharmacogenomics
Figure 1.3:    Global Pharmacogenomics (PGx) Market, 2018-2028
Figure 2.1:    Iceberg Analysis - Global Pharmacogenomics Market
Figure 2.2:    Number of Deaths by Top 18 Infectious Diseases, 2015
Figure 2.3:    Number of Deaths (in Millions) by Different Forms of Cancer, 2018
Figure 2.4:    Benefits of Multiplexing Reactions
Figure 3.1:    Share of Key Developments and Strategies, January 2016 – April 2019
Figure 3.2:    Product Launches Share (by Company), January 2016 – April 2019
Figure 3.3:    Product Approvals Share (by Company), January 2016 – April 2019
Figure 3 4:    Synergistic Activities Share (by Company), January 2016 – April 2019
Figure 3.5:    Market Share Analysis for the Global Pharmacogenomics Market, 2017
Figure 3.6:    Market Share Analysis for the Global Pharmacogenomics Market, 2018
Figure 3.7:    Growth Share Matrix for Global Pharmacogenomics Market (by Companies), 2018
Figure 3.8:    Overall Industry Attractiveness, 2018 and 2028
Figure 3.9:    Overall Impact of Bargaining Power of Suppliers
Figure 3.10:    Overall Impact of Bargaining Power of Buyers
Figure 3.11:    Overall Impact of Threat of New Entrants
Figure 3.12:    Overall Impact of Threat of Substitute Products
Figure 3.13:    Overall Impact of Intensity of Competitive Rivalry
Figure 4.1:    Components Considered for Clinical Evidence as per the IVDR
Figure 4.2:    Process of Medical Device Designation by the MHLW and PMDA
Figure 4.3:    Share of Patents (by Ownership), 2016-2019
Figure 5.1:    Global Pharmacogenomics Market (by Service)
Figure 5.2:    Global Pharmacogenomics Market (by Service), 2018 and 2028
Figure 5.3:    Global Pharmacogenomics Market (by Genotyping Service), 2018-2028
Figure 5.4:    Global Pharmacogenomics Market (by SNP Identification Service), 2018-2028
Figure 5.5:    Global Pharmacogenomics Market (by Pharmacogenetic Testing Service), 2018-2028
Figure 5.6:    Global Pharmacogenomics Market (by Other Testing Services), 2018-2028
Figure 6.1:    Global Pharmacogenomics Market (by Application)
Figure 6.2:    Global Pharmacogenomics Market (by Application), 2018 and 2028
Figure 6.3:    Global Pharmacogenomics Market (by Oncology), 2018-2028
Figure 6.4:    Global Pharmacogenomics Market (by Infectious Diseases), 2018-2028
Figure 6.5:    Global Pharmacogenomics Market (by Neurology/Psychiatry), 2018-2028
Figure 6.6:    Global Pharmacogenomics Market (by Cardiovascular), 2018-2028
Figure 6.7:    Global Pharmacogenomics Market (by Other Applications), 2018-2028
Figure 7.1:    Global Pharmacogenomics Market (by Technology)
Figure 7.2:    Global Pharmacogenomics Market (by Technology), 2018 and 2028
Figure 7.3:    Global Pharmacogenomics Market (by PCR), 2018-2028
Figure 7.4:    Global Pharmacogenomics Market (by Microarray), 2018-2028
Figure 7.5:    Evolution of Sequencing for Molecular Diagnostics
Figure 7.6:    Global Pharmacogenomics Market (by Sequencing), 2018-2028
Figure 7.7:    Global Pharmacogenomics Market (by Other Technologies), 2018-2028
Figure 8.1:    Global Pharmacogenomics Market (by End User)
Figure 8.2:    Global Pharmacogenomics Market (by End User), 2018 and 2028
Figure 8.3:    Global Pharmacogenomics Market (by Research Organizations), 2018-2028
Figure 8.4:    Research Organizations (by Service), Share 2018 and 2028
Figure 8.5:    Global Pharmacogenomics Market (by Pharmaceutical Companies), 2018-2028
Figure 8.6:    Pharmaceutical Companies (by Service), 2018 and 2028
Figure 8.7:    Global Pharmacogenomics Market (by Diagnostic Centers), 2018-2028
Figure 8.8:    Diagnostics Centers (by Service), 2018 and 2028
Figure 8.9:    Global Pharmacogenomics Market (by Other End Users), 2018-2028
Figure 9.1:    Global Pharmacogenomics Market (by Region), 2018 and 2028
Figure 9.2:    Global Pharmacogenomics Market (by Region), 2018-2028
Figure 9.3:    Global Pharmacogenomics Market Share (by Region), 2018
Figure 9.4:    Global Pharmacogenomics Market Share (by Region), 2028
Figure 9.5:    North America Pharmacogenomics Market, 2018-2028
Figure 9.6:    North America: Market Dynamics
Figure 9.7:    North America Pharmacogenomics Market (by Country), 2018-2028
Figure 9.8:    The U.S. Pharmacogenomics Market, 2018-2028
Figure 9.9:    Canada Pharmacogenomics Market, 2018-2028
Figure 9.10:    North America Pharmacogenomics Market (by Application), 2018 and 2028
Figure 9.11:    North America Pharmacogenomics Market (by Service), 2018 and 2028
Figure 9.12:    Europe Pharmacogenomics Market, 2018-2028
Figure 9.13:    Europe: Market Dynamics
Figure 9.14:    Europe Pharmacogenomics Market (by Country), 2018-2028
Figure 9.15:    Germany Pharmacogenomics Market, 2018-2028
Figure 9.16:    The U.K. Pharmacogenomics Market, 2018-2028
Figure 9.17:    France Pharmacogenomics Market, 2018-2028
Figure 9.18:    Italy Pharmacogenomics Market, 2018-2028
Figure 9 19:    Spain Pharmacogenomics Market, 2018-2028
Figure 9 20:    Denmark Pharmacogenomics Market, 2018-2028
Figure 9.21:    The Netherlands Pharmacogenomics Market, 2018-2028
Figure 9.22:    Rest-of-Europe Pharmacogenomics Market, 2018-2028
Figure 9.23:    Europe Pharmacogenomics Market (by Application), 2018 and 2028
Figure 9.24:    Europe Pharmacogenomics Market (by Service), 2018 and 2028
Figure 9.25:    Asia-Pacific Pharmacogenomics Market, 2018-2028
Figure 9.26:    APAC: Market Dynamics
Figure 9.27:    APAC Pharmacogenomics Market (by Country), 2018-2028
Figure 9.28:    Japan Pharmacogenomics Market, 2018-2028
Figure 9.29:    China Pharmacogenomics Market, 2018-2028
Figure 9.30:    Australia Pharmacogenomics Market, 2018-2028
Figure 9.31:    India Pharmacogenomics Market, 2018-2028
Figure 9.32:    Singapore Pharmacogenomics Market, 2018-2028
Figure 9.33:    RoAPAC Pharmacogenomics Market, 2018-2028
Figure 9.34:    Asia-Pacific Pharmacogenomics Market (by Application), 2018 and 2028
Figure 9.35:    Asia-Pacific Pharmacogenomics Market (by Service), 2018 and 2028
Figure 9.36:    Latin America Pharmacogenomics Market, 2018-2028
Figure 9.37:    Latin America: Market Dynamics
Figure 9.38:    Latin America Pharmacogenomics Market (by Country), 2018-2028
Figure 9.39:    Brazil Pharmacogenomics Market, 2018-2028
Figure 9.40:    Mexico Pharmacogenomics Market, 2018-2028
Figure 9.41:    Rest-of-Latin America Pharmacogenomics Market, 2018-2028
Figure 9.42:    Latin America Pharmacogenomics Market (by Application), 2018 and 2028
Figure 9.43:    Latin America Pharmacogenomics Market (by Service), 2018 and 2028
Figure 9.44:    RoW Pharmacogenomics Market, 2018-2028
Figure 9.45:    RoW Pharmacogenomics Market (by Application), 2018 and 2028
Figure 9.46:    RoW Pharmacogenomics Market (by Service), 2018 and 2028
Figure 10.1:    Total Number of Companies Profiled
Figure 10.2:    Abbott Laboratories: Overall Product Portfolio
Figure 10.3:    Abbott Laboratories: Overall Financials, 2016-2018
Figure 10.4:    Abbott Laboratories: Revenue (by Segment), 2016-2018
Figure 10.5:    Abbott Laboratories: Revenue Split for Diagnostics, 2016-2018
Figure 10.6:    Abbott Laboratories: Revenue (by Region), 2016-2018
Figure 10.7:    Abbott Laboratories: R&D Expenditure, 2016-2018
Figure 10.8:    Abbott Laboratories: SWOT Analysis
Figure 10.9:    Admera Health, LLC: Overall Product Portfolio
Figure 10.10:    Admera Health, LLC: SWOT Analysis
Figure 10.11:    Agena Biosciences, Inc.: Overall Product Portfolio
Figure 10.12:    Agena Biosciences, Inc.: SWOT Analysis
Figure 10.13:    Product Portfolio: Cancer Genetics, Inc.
Figure 10.14:    Cancer Genetics, Inc.: Overall Financials, 2016-2018
Figure 10.15:    Cancer Genetics, Inc.: Revenue (by Segment), 2016-2018
Figure 10.16:    Cancer Genetics, Inc.: R&D Expenditure, 2016-2018
Figure 10.17:    Cancer Genetics, Inc.: SWOT Analysis
Figure 10.18:    Dynamic DNA Laboratories: Overall Product Portfolio
Figure 10.19:    Dynamic DNA Laboratories: SWOT Analysis
Figure 10.20:    F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 10.21:    F. Hoffmann-La Roche Ltd: Overall Financials, 2016-2018
Figure 10.22:    F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2016-2018
Figure 10.23:    F. Hoffmann-La Roche Ltd: Revenue Split for Diagnostics, 2016-2018
Figure 10.24:    F. Hoffmann-La Roche Ltd: Revenue (by Region), 2016-2018
Figure 10.25:    F. Hoffmann-La Roche Ltd: R&D Expenditure, 2016-2018
Figure 10.26:    F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 10.27:    geneOmbio Technologies Pvt Ltd.: Overall Product Portfolio
Figure 10.28:    geneOmbio Technologies Pvt Ltd.: SWOT Analysis
Figure 10.29:    Genomic Health, Inc.: Overall Product Portfolio
Figure 10.30:    Genomic Health, Inc.: Overall Financials, 2016-2018
Figure 10.31:    Genomic Health, Inc.: Revenue (by Segment), 2016-2018
Figure 10.32:    Genomic Health, Inc.: Revenue (by Region), 2016-2018
Figure 10.33:    Genomic Health, Inc.: R&D Expenditure, 2016-2018
Figure 10.34:    Genomic Health, Inc.: SWOT Analysis
Figure 10.35:    Illumina, Inc.: Overall Product Portfolio
Figure 10.36:    Illumina, Inc.: Overall Financials, 2016-2018
Figure 10.37:    Illumina, Inc.: Revenue (by Segment), 2016-2018
Figure 10.38:    Illumina, Inc.: Revenue (by Region), 2016-2018
Figure 10.39:    Illumina, Inc.: R&D Expenditure, 2016-2018
Figure 10.40:    Illumina, Inc.: SWOT Analysis
Figure 10.41:    Laboratory Corporation of America Holdings: Overall Product Portfolio
Figure 10.42:    Laboratory Corporation of America Holdings: Overall Financials, 2016-2018
Figure 10.43:    Laboratory Corporation of America Holdings: Revenue (by Segment), 2016-2018
Figure 10.44:    Laboratory Corporation of America Holdings: Revenue (by Region), 2018
Figure 10.45:    Laboratory Corporation of America Holdings: SWOT Analysis
Figure 10.46:    Myriad Genetics, Inc.: Overall Product Portfolio
Figure 10.47:    Myriad Genetics, Inc.: Overall Financials, 2016-2018
Figure 10.48:    Myriad Genetics, Inc.: Revenue (by Business Segment), 2016-2018
Figure 10.49:    Myriad Genetics, Inc.: SWOT Analysis
Figure 10.50:    Pathway Genomics Corporation: Overall Product Portfolio
Figure 10.51:    Pathway Genomics Corporation: SWOT Analysis
Figure 10.52:    QIAGEN N.V.: Overall Product Portfolio
Figure 10.53:    QIAGEN N.V.: Overall Financials, 2016-2018
Figure 10.54:    QIAGEN N.V.: Revenue (by Segment), 2016-2018
Figure 10.55:    QIAGEN N.V.: Revenue (by Region), 2016-2018
Figure 10.56:    QIAGEN N.V.: R&D Expenditure, 2016-2018
Figure 10.57:    QIAGEN N.V.: SWOT Analysis
Figure 10.58:    Product Portfolio: Quest Diagnostics Incorporated
Figure 10.59:    Quest Diagnostics Incorporated: Overall Financials, 2016-2018
Figure 10.60:    Quest Diagnostics Incorporated: Revenue (by Segment), 2016-2018
Figure 10.61:    Quest Diagnostics Incorporated: SWOT Analysis
Figure 10.62:    Thermo Fisher Scientific Inc.: Overall Product Portfolio
Figure 10.63:    Thermo Fisher Scientific Inc.: Overall Financials, 2016-2018
Figure 10.64:    Thermo Fisher Scientific Inc.: Revenue (by Segment), 2016-2018
Figure 10.65:    Thermo Fisher Scientific Inc.: Revenue (by Region), 2016-2018
Figure 10.66:    Thermo Fisher Scientific Inc.: R&D Expenditure, 2016-2018
Figure 10.67:    Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 10.68:    Transgenomic, Inc.: Overall Product Portfolio
Figure 10.69:    Transgenomic, Inc.: SWOT Analysis
Figure 10.70:    23and Me, Inc.: Overall Product Portfolio
Figure 10.71:    OneOme, LLC: Overall Product Portfolio
Figure 11.1:    Global Pharmacogenomics Market Segmentation
Figure 11.2:    Global Pharmacogenomics Market Research Methodology
Figure 11.3:    Primary Research
Figure 11.4:    Secondary Research
Figure 11.5:    Data Triangulation
Figure 11.6:    Bottom-up Approach (Segment-wise Analysis)
Figure 11.7:    Top-down Approach (Segment-wise Analysis)
Figure 11.8:    Assumptions and Limitations
Figure 11.9:    Considered Factors for Data Prediction and Modeling

As World Health Organization states, the global healthcare expenditure is on the course to be an exorbitant $8.5 trillion in 2020, owing to an increasing economic burden of chronic diseases, which are estimated to constitute almost 43% of the global economic burden. Thus, the escalating demand for better treatment outcome is leading to an ascending need for preventive, precise healthcare, and tailored medication. The growth of the precision medicine market over the last few years (2010-2017) has been colossal and has significantly contributed to giving rise to a number of parallel fields of study and possible healthcare implementations. Pharmacogenomics is defined as the study of the whole genome with respect to drug response, is consistently revolutionizing healthcare at the interface of precision medicine, with implications for drug development in order to provide superior treatment. 

The rapid growth of clinically relevant pharmacogenomic knowledge and drugs used for patient treatment in virtually every medical specialty, is consistently aiding in the evolution of prevention-based treatment. With a critical role in the global precision medicine phenomenon, pharmacogenomics is responsible for ensuring safe and effective application of targeted therapeutics. The services offered by the major players in the pharmacogenomics market encompass categories such as genotyping, single nucleotide polymorphism (SNP) identification, and pharmacogenetic testing, among others. Also, several diagnostics and pharmaceutical companies are presently undertaking synergistic activities for the development of NGS-, PCR-, IHC-, ISH-, microarray-, or mass spectrometry-based pharmacogenomics for the applications in several disease indications, in order to enable efficient diagnosis, treatment selection, dosage selection, and treatment monitoring. The applications of pharmacogenomics primarily include oncology, infectious diseases, neurology/psychiatry, and cardiovascular, among others. Aside from the discovery of effective biomarkers for the development of efficient pharmacogenomics kits, obtaining regulatory approval is essential. The efficiency and effectiveness primarily depend upon the approval of a pharmacogenomics in the stratification of the patient population as responders and non-responders to aid in the selection of appropriate treatment. Therefore, the entire regulatory and approval process necessitates close collaboration between the manufacturer of the targeted drug and the manufacturer of corresponding genetic test. Besides research organizations, pharmaceutical companies, and diagnostic centers, among others, are also prominent end users of pharmacogenomics.

This growth has been primarily attributed to the major drivers in this market such as a highly increasing prevalence of infectious diseases and various types of cancer globally, increase in adoption of personalized medicine shifting the paradigm from reaction to prevention on a global level, increasing rate of adverse drug reaction, and surge in usage of pharmacogenomics for drug discovery and development. These individualized care regimes are improving quality of life of the patients and reducing economic, societal, and clinical burden, projecting a future of prosperity.

Presently, service categories within the pharmacogenomics market include genotyping, SNP identification, and pharmacogenetic testing. Till date, the healthcare industry has witnessed a number of successful products and services that have contributed significantly to the enhancement of technological advancements in making treatment more precise. As of 2018, pharmacogenomics, though minimally reimbursed, can be seen to have large-scale exposure in almost all the developed countries. However, with the rapid advancements taking place and an exponential progression in the number of companies entering the space, access to consumers is bound to become easier, thus significantly increasing the exposure in less-developed countries. The global pharmacogenomics market has been witnessing a steady growth since the end of the Human Genome Project in 2003. The market is expected to continue to grow with a double digit CAGR of 6.98% during the forecast period, 2019-2028. Growing at a CAGR of 6.42% during the forecast period of 2019-2028, the genotyping service segment is anticipated to generate a value of $3.54 billion in 2028. However, the global market for pharmacogenetic testing services is anticipated to grow at the fastest CAGR of 8.95% during the forecast period 2019-2028.

The purpose of the study is to gain a holistic view of the global pharmacogenomics market in terms of various factors influencing the same, including regulatory reforms, and technological advancements. The market has been segmented into ‘services’, ‘applications’, ‘technologies’, ‘end users’, and ‘regions’. The scope of this report is centered upon conducting a detailed study of the products and services allied with the pharmacogenomics market. In addition, the study also includes the exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each service, application, technology, end user, region, and company, as well as other vital information with respect to global pharmacogenomics market.

Based on the region, the global pharmacogenomics market is segmented into North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World (RoW). North America is the leading contributor to the global pharmacogenomics market and was responsible for a 50.89% share of the global market values in 2018. However, the Asia-Pacific region is expected to grow at the fastest pace among all other regions with a CAGR of 8.82% during the forecast period 2019-2028.

The key players who have been contributing significantly to the global pharmacogenomics market include Abbott Laboratories, F. Hoffmann-La Roche Ltd, Illumina, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics, Incorporated, Myriad Genetics, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., and Genomic Health, Inc., among others.

We understand that your business need specific answers pertaining to the market. And , therefore, we do provide customised research tailored to your need.

With the purchase of this report, you are entitled to certain degree of free customisation within the scope of the study.

Do get in touch to help us understand how we can serve u better with a custom solution to your research needs. We assure quick turnaround for your pressing business requirements.

Contact Information


Name *
Work Email *
 
Company Name *
Designation*
 
 
Contact No. *
Other Details
 
 

Write the characters in the image above
 
 
* Required Fields

Get yourself updated on key emerging technology markets

Know about our market intelligence coverage in key sectors